Literature DB >> 32235897

Selumetinib benefits children with inoperable plexiform neurofibromas.

David Killock1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32235897     DOI： 10.1038/s41571-020-0361-7

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Selumetinib in Children with Inoperable Plexiform Neurofibromas.

Authors:  Andrea M Gross; Pamela L Wolters; Eva Dombi; Andrea Baldwin; Patricia Whitcomb; Michael J Fisher; Brian Weiss; AeRang Kim; Miriam Bornhorst; Amish C Shah; Staci Martin; Marie C Roderick; Dominique C Pichard; Amanda Carbonell; Scott M Paul; Janet Therrien; Oxana Kapustina; Kara Heisey; D Wade Clapp; Chi Zhang; Cody J Peer; William D Figg; Malcolm Smith; John Glod; Jaishri O Blakeley; Seth M Steinberg; David J Venzon; L Austin Doyle; Brigitte C Widemann
Journal:  N Engl J Med       Date:  2020-03-18       Impact factor: 91.245
  1 in total
  3 in total

1.  Epidemiological profile and clinical characteristics of 491 Brazilian patients with neurofibromatosis type 1.

Authors:  Luiz Guilherme Darrigo Junior; Victor Evangelista de Faria Ferraz; Marina Candido Visontai Cormedi; Luissa Hikari Hayashi Araujo; Mariana Prado Silva Magalhães; Rafaella Curis Carneiro; Luis Henrique Nunes Sales; Mendel Suchmacher; Karin Soares Cunha; Aguinaldo Bonalumi Filho; David Rubem Azulay; Mauro Geller
Journal:  Brain Behav       Date:  2022-05-04       Impact factor: 3.405

2.  A critical role of AREG for bleomycin-induced skin fibrosis.

Authors:  Mary Yinghua Zhang; Shuyi Fang; Hongyu Gao; Xiaoli Zhang; Dongsheng Gu; Yunlong Liu; Jun Wan; Jingwu Xie
Journal:  Cell Biosci       Date:  2021-02-23       Impact factor: 7.133

3.  Improving the lives of children with neurofibromatosis type 1.

Authors:  Yoo-Mi Kim
Journal:  Clin Exp Pediatr       Date:  2020-09-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.